http://orcid.org/0000-0002-4794-9809
Figures
Abstract
Aim
To evaluate the potential value of using a serological assay to quantitate the hepatitis C virus core antigen (HCV-Ag) when monitoring patients with chronic hepatitis C being treated with direct-acting antivirals (DAAs).
Methods
Ninety-six patients treated with DAAs, either alone (91) or in combination with PEG interferon (5), were tested for HCV-RNA and for HCV-Ag at baseline and at weeks 2, 4, 8 and 12 during treatment and 12 weeks after completion. The concordance and correlation between the viral parameters as well as the respective kinetics during and after treatment were evaluated.
Results
A sustained viral response (SVR) was achieved in 82 patients (91%), whereas 11 relapsed (R) and 1 showed a virological breakthrough while receiving treatment. HCV-RNA and HCV-Ag showed good concordance (kappa = 0.62) and correlation. No significant differences between SVR and R was observed in either assay at 2 and 4 weeks after the start of treatment. At 8 weeks, HCV-Ag showed higher accuracy than HCV-RNA (AUC: 0.74 vs. 0.55) and there was a significantly greater decrease from baseline in SVR than in R (4.01 vs. 3.36 log10; p<0.05).
Citation: Loggi E, Galli S, Vitale G, Di Donato R, Vukotic R, Grandini E, et al. (2017) Monitoring the treatment of hepatitis C with directly acting antivirals by serological and molecular methods. PLoS ONE 12(11): e0187755. https://doi.org/10.1371/journal.pone.0187755
Editor: Ming-Lung Yu, Kaohsiung Medical University Chung Ho Memorial Hospital, TAIWAN
Received: July 13, 2017; Accepted: October 25, 2017; Published: November 10, 2017
Copyright: © 2017 Loggi et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: All relevant data are within the paper and its Supporting Information files.
Funding: The laboratory reagents (serological determinations) have been provided by Abbott Diagnostics, free of charge. The Abbott Diagnostics partially supported the research providing the research materials, following an agreement for an Investigator Initiated Study (IIS), but did not play a role in the study design, data collection, decision to publish, or preparation of the manuscript. No Authors' salaries have been provided. The Co-Author, Dr. Claudio Galli is currently employed by Abbott Diagnostics as the Associate Director, Medical Scientific Liaison Europe contributed to data analysis, as stated in Author roles in the Author Contributions section.
Competing interests: Dr. Claudio Galli is currently employed by Abbott Diagnostics as the Associate Director, Medical Scientific Liaison Europe. The other Authors have no conflicting interests to declare. The Commercial affiliation does not alter our adherence to PLOS ONE policies on sharing data and materials. The providing of laboratory reagents does not alter our adherence to PLOS ONE policies on sharing data and materials.
Introduction
The treatment of chronic hepatitis C virus infection (CHC) has been revolutionized by the introduction of direct-acting antivirals (DAAs), which are agents that can interfere with different steps of the replicative cycle of a virus [1, 2]. This molecular approach replaces the standard treatment based on a combination of pegylated interferon α (peg-IFNα) and ribavirin (RBV), which acts on several non-specific pathways to boost the antiviral immune response [3]. DAAs lead to viral eradication in more than 90% of patients [2]. In addition to being significantly more effective than interferon-based therapy for curing the infection, these treatments have important additional benefits, including a tolerability profile that makes them suitable for previously excluded patients [4], simplified management due to the shorter treatment duration and an oral route of administration. Unfortunately, the high costs of these therapies currently limit the access to these drugs, thereby requiring strict patient selection and blocking the drugs’ widespread use [5].
Measuring HCV-RNA by using sensitive molecular techniques has been the gold standard for treatment monitoring in the era of IFN-based treatment. Baseline viremia and an early drop in HCV-RNA levels are the strongest elements for predicting the treatment outcome, and viremia measurement during treatment is crucial for establishing the treatment duration and assessing the response-guided therapy [6].
The introduction of DAA regimens has changed virological monitoring because the baseline HCV-RNA levels no longer seem to be response-predictors and because detectable residual HCV-RNA at the end of DAA therapies can occur frequently but does not have an association with subsequent viral relapse [7]. Consistent with this assumption, no futility/stopping rules have been established to date. To simplify treatment monitoring, hepatitis C core antigen (HCV-Ag) is emerging as a new tool for diagnosis and treatment monitoring in CHC.
HCV-Ag is a highly conserved and antigenic protein that is released into the plasma [8, 9] and can be easily quantified due to the availability of an automated platform. HCV-Ag quantification is an indirect measure of viral replication [10, 11], and it has been proven to be useful for treatment monitoring of IFN-based therapy [12, 13] and has even recently been used to monitor DAA-based therapy [14, 15].
In this study, we aimed to assess the accuracy of HCV-Ag for monitoring therapy efficacy compared to RT-PCR in a population of multi-genotype CHC patients who were undergoing treatment with different DAA regimens in a real-life clinical setting.
Patients and methods
Patients
Among all the consecutive all-genotype CHC patients who received a DAA-based treatment in between June 2013 and December 2015 at the ITEC Outpatient Clinics of Azienda Ospedaliero-Universitaria di Bologna (Bologna, Italy), 96 CHC patients were selected for the analysis based on the availability of longitudinal serum samples.
The inclusion criteria were adult age (≥18 years), CHC infection confirmed by serum HCV-RNA using an RT-PCR-based method and, in particular, fulfilling the criteria to be eligible for treatment with DAA according to the indications established by the Italian government (Agenzia Italiana del Farmaco-AIFA). The patient population consisted of the following 3 groups:
- Patients with advanced disease with METAVIR stage F3 (advanced fibrosis) or F4 (cirrhosis);
- Patients with HCV recurrence after liver transplantation;
- Patients with extrahepatic manifestations, such as cryoglobulinemia and B-cell lymphoproliferative disease.
The DAA regimen, treatment duration and addition of weight-based ribavirin (RBV) were determined by the treating physician according to current guidelines.
The study was approved by the Ethical Committee of Azienda Ospedaliera di Bologna, (Bologna, Italy), and the patients provided written informed consent.
Study assessments
SVR was defined as HCV-RNA that was undetectable 12 weeks after completing treatment (SVR12). Post-treatment relapse (R) was defined as confirmed HCV-RNA ≥15 IU/ml during a follow-up in patients with undetectable HCV-RNA at the end of treatment.
Viral breakthrough was defined as a ≥1 log10 IU/ml increase from the nadir of HCV-RNA or when HCV-RNA ≥15 IU/ml after HCV-RNA was undetectable during the treatment.
HCV-RNA testing and HCV-Ag determinations
The HCV-RNA levels were measured with the COBAS AmpliPrep/COBAS TaqMan HCV Quantitative Test, version 2.0 (Roche; lower limit of quantitation = 15 IU/mL) at baseline as well as after 2, 4, 8, 12, 16 and 24 weeks for patients treated until the 24th week (W2, W4, W8, W12, W16, W24) during treatment. Follow-up measurements were collected at 4 and 12 weeks post-treatment. HCV-RNA was positive if the level was >15 IU/mL, whereas detectable but not measurable HCV-RNA levels were reported as <15 IU/mL and scored as a gray zone. Only samples with an undetectable level of HCV-RNA were considered negative. The HCV genotype and subtype were determined using the Siemens VERSANT HCV Genotype INNO-LiPA 2.0 Assay.
HCV-Ag was retrospectively measured in serum samples obtained at the same time points as the HCV-RNA using an automated chemiluminescent HCV-Ag assay (Abbott Diagnostics, Wiesbaden, Germany) that was performed on the Abbott ARCHITEC T i2000SR platform according to the manufacturer’s instructions. The cut-off value for HCV-Ag detection was 3.0 fmol/L. Levels below 3.0 fmol/L were considered non-reactive, levels between 3 and 10 fmol/L represented the “gray” zone, and levels above 10 fmol/L were positive for HCV-Ag. The dynamic range of the test was 3–20,000 fmol/L, and an automated dilution extended this range to 180,000 fmol/L.
Statistical analysis
Quantitative variables were expressed as the median and range, and categorical variables were expressed as a number count and proportions. Chi-square or Fisher’s exact test and the Mann-Whitney test were used to compare categorical and continuous variables when appropriate. Correlations were determined with a non-parametric Spearman correlation and kappa statistics. The accuracy of HCV-RNA and HCV-Ag for assessing SVR was evaluated by receiver-operating characteristics (ROC) curves.
A p value of <0.05 was considered statistically significant. All analyses were performed using SPSS for Windows (Statistical Package for the Social Sciences, version 21.0, Armonk, New York, NY, USA), and GraphPad Prism, version 5.
Results
Patients and response to treatment
The demographics and clinical and virological features of the enrolled patients are listed in Table 1. The treatment regimens were quite heterogeneous, although most patients were treated with an IFN-free course (91, or 95%), but 5 patients (5%) were treated with a combination of Peg-IFN, Ribavirin and DAA. The duration of treatment was 12 weeks for 65 patients and 24 weeks for 31 patients. Most patients (63%) were cirrhotic, and twelve had received a liver transplantation with HCV recurrence.
Overall, SVR12 was achieved in 82 of the 96 patients (85% intention to treat analysis), 11 patients experienced a relapse (11%) and only one showed a breakthrough after 6 weeks from the start of treatment. The remaining 2 patients died due to causes unrelated to liver disease before the completion of the follow-up period, but they were HCV-RNA negative until the last available time point. Relapses were diagnosed in 8 patients after 4 weeks from treatment completion and in 3 patients after 12 weeks. The occurrence of viral relapse was unrelated to the previous treatment (10.5% among treatment-naïve patients, 12.5% among treated patients).
Baseline HCV-RNA and HCV-Ag values and correlation
All patients were positive for both parameters at the start of treatment. The baseline values of HCV-RNA ranged from 6,14x103 to 533x106 IU/mL (Table 1). The distribution of levels showed that most patients (54/96; 56.3%) displayed levels higher than 1x106 IU/mL, whereas 39 of the 96 patients (40.6%) showed values ranging from 1x105 to 1x106, and the remaining 3 had values lower than 105 IU/mL. The baseline values for HCV-Ag ranged from 10.79 to >20,000 fmol/L (Table 1). The levels distribution showed that most patients (71/96, 74%) displayed levels higher than 1,000 fmol/L, whereas 20 of the 96 patients (20.8%) showed values ranging from 100 to 1,000 and only 5 (5.2%) had values lower than 100 fmol/L. Interestingly, the patients with low HCV-RNA or low HCV-Ag levels at baseline were not the same patients. Neither baseline HCV-RNA nor HCV-Ag levels were different between SVR and non-SVR patients (median HCV-RNA: 1.18x106 vs 2.2 x106 IU/mL p = 0.219; median HCV-Ag: 2,974 vs 4,170 fmol/L, p = 0.358, respectively). The correlation between HCV-RNA and HCV-Ag at baseline was good (Spearman r = 0.767, 95% confidence interval 0.66–0.84, p = 0.000).
HCV-RNA and HCV-Ag: patterns, concordance and accuracy
As expected, the decrease in HCV-RNA during treatment was very rapid since the rate of negativity for HCV-RNA went from 16% after 2 weeks to 55% after 4 weeks and 99% after 8 weeks of treatment (Fig 1). The kinetics of HCV-Ag were different because negativity was already seen at 63% after 2 weeks but showed a slower progression during treatment (74% after 4 weeks, 83% after 8 weeks) (Fig 1). At the end of treatment, all patients except the breakthrough case were negative for both HCV-RNA and HCV-Ag. At the time of virological relapse, all 11 patients were positive for both HCV-RNA (range: 5,244 to 1.74x107 IU/mL) and HCV-Ag (range: from 10.13 to >20,000 fmol/L).
Over the complete course of treatment, including baseline and follow-up, a total of 690 samples were assayed for both HCV-RNA and HCV-Ag. Of those, the qualitative concordance between the measures was good (92%; kappa statistics 0.62) (Table 2). Discordant results were observed on both sides, with 39 samples being positive for HCV-RNA and with no detectable HCV-Ag and 13 samples showing opposite outcomes. The latter samples were obtained during treatment and at 4 and 8 weeks after the start of therapy. The median level of HCV-RNA in the 39 samples negative for HCV-Ag was 55 IU/mL with only one specimen (2.6%) yielding a value >1,000 IU/mL. Conversely, the median level of HCV-Ag in the 13 samples negative for HCV-RNA was 15 fmol/L, with only one sample (7.7%) yielding a value >100 fmol/L. Those discrepancies did not account for the different behavior of HCV-RNA and HCV-Ag over the monitoring course because the levels varied with a consistent pattern in SVR and in R (Fig 2). The only difference was a slower decrease in HCV-Ag, which explains how samples were positive for HCV-Ag and had undetectable HCV-RNA.
Monitoring profiles for HCV-RNA and HCV-Ag of a representative patient with sustained viral response after 24 weeks of treatment with Sofosbuvir + Ribavirin (2a) and of a patient with relapse after 24 weeks of treatment with Sofosbuvir + Simeprevir + Ribavirin (2b). The horizontal axis reports the dates of blood draws (month, day) from June 2015 to April 2016 after the start of treatment.
The accuracy of HCV-RNA and HCV-Ag towards SVR was assessed at W2, W4 and W8 during treatment. HCV-RNA levels did not show a strong predictive value for SVR because the area under the ROC curve (AUC) was 0.65 at W2, 0.70 at W4 and 0.55 at W8 (Fig 3A). Indeed, the latter figure is a purely mathematical estimate because all patients with SVR or R did not show detectable viral RNA at that time. HCV-Ag was similarly a poor predictor of SVR at W2 and W4, with AUCs of 0.63 and 0.62, respectively (Fig 3B). However, at W8, the AUC for HCV-Ag was the highest (0.74); this occurred at the same time point when the AUC for HCV-RNA was the lowest, as observed previously. When the kinetics of HCV-RNA and HCV-Ag in the 82 patients infected by HCV genotype 1 (84.5%) were compared to the 14 infected by other genotypes (Table 1), no significant differences were observed.
Receiver-operating characteristics (ROC) curves for HCV-RNA (3a) and HCV-Ag (3b) after 2, 4 and 8 weeks after starting treatment with DAAs. The horizontal axis reports the dates of blood draws (month, day) from June 2015 to April 2016 after the start of treatment.
Finally, as a further measure of the efficacy of antiviral treatment, the decrease (expressed in log10 values) in HCV-RNA and HCV-Ag at different time points compared to baseline was calculated (Fig 4). Again, the differences between SVR and R were not significant for HCV-RNA, whereas for HCV-Ag, a significant difference (<0.05) was observed at W8, with a median decrease of 4.23 log10 in SVR compared to 3.36 in R (p<0.05). However, when considering the patients treated for 12 weeks separately from those treated for 24 weeks, this difference was no longer significant.
W = weeks after the start of treatment.
Discussion
The outcome of any pharmacological therapy for liver disease due to HCV is still based on testing for HCV-RNA with sensitive techniques because the absence of circulating viral RNA defines both patient responsiveness to drugs and the sustained viral response after treatment. The purpose of HCV-RNA testing may differ according to the type of therapy. Although monitoring patients after 2 and/or 4 weeks of treatment is still recommended for regimens such as interferon in interferon-free DAA schedules, testing after 2/4 weeks is optional and is used to verify adherence [16]. Indeed, negativity for HCV-RNA is obtained early by almost all subjects due to the direct effects of DAAs on viral replication. This conclusion was confirmed in the present study, in which 84% of the patients showed undetectable RNA after 4 weeks and 100% of the patients had the same result after 8 weeks, regardless of the treatment outcome.
However, the same guidelines [16][17] suggest that although doing so provides less strength (A2 level), monitoring may be simplified to increase access to care by skipping assessments during treatment and determining HCV-RNA only at baseline and 12 or 24 weeks after the end of therapy (SVR12 or SVR24, respectively) (A2). In contrast, the most recent guidelines from the American Association for the Study of Liver Disease (AASLD) still recommend quantitative HCV viral load testing after 4 weeks of therapy [17], and the Asian Pacific Association for the Study of the Liver (APASL) guidelines that were issued last year indicate generically that monitoring the HCV loads during treatment is important for response-guided therapy to determine the futility, treatment protocol, and duration [18]. Therefore, a consensus on monitoring for DAA treatment has yet to be reached, and the positive predictive value for SVR of HCV-RNA testing still needs to be ascertained. For this purpose, Maasoumy et al [7] studied the HCV-RNA kinetics from 298 patients with HCV genotypes 1 to 5a who were treated with different Sofosbuvir-based regimens, and they reported that lower levels were attained by SVR patients compared to R in both genotype 1 and genotype 3 infections. For the latter group, the authors indicated that HCV-RNA levels <45 IU/mL or <60 IU/mL (according to the method employed for HCV-RNA quantitation) after 2 weeks of treatment were predictive of treatment outcome and yielded 100% sensitivity. Conversely, the specificity was not outstanding because levels below the proposed thresholds were also attained in 29% and 33% or R, respectively. We were not able to confirm these results, at least for patients with HCV genotype 1 infection (73.5% of our cases), because no significant differences in HCV-RNA levels or decreases could be observed between SVR and R at week 2 or 4 during treatment. This result is relevant because the percentage rates of SVR may currently be lower than the rates reported in the literature, which most likely occurred because of advanced disease and a suboptimal regimen (according to the information available at the time of therapy starting) for some patients (Table 1). In our experience, we observed an 11% rate of R that was unrelated to previous treatment failure and/or other clinical data, and a similar rate (14%) was recently reported by Aghemo et al. [14].
A new approach for DAA monitoring has also been included in the EASL 2017 guidelines. Although the standard methodology is still real-time PCR with high sensitivity (≤15 IU/ml), measuring HCV-Ag has been recommended (A1 level) as an alternative to PCR “when HCV-RNA is not available or not affordable” [16]. HCV-Ag is also recommended in the same guidelines as a way to identify people with ongoing HCV infection (i.e., viral replication) among those individuals who are found to be positive for anti-HCV antibodies. Consistently, the same approach has also been envisioned by the World Health Organization in a very recent document designed to update the diagnostic criteria for both hepatitis B virus and HCV infections [19].
The timing for HCV-Ag testing in treatment monitoring will be the same as HCV-RNA, i.e., at baseline, optional between weeks 2 and 4, at the end of treatment and at the end of post-treatment follow-up [16]. The data reported here are more complete because we could assess both markers of HCV replication at multiple time points during treatment. Overall, the HCV-Ag trends mimicked those of HCV-RNA with different kinetics. The antigen levels decrease more rapidly in the early stages (63% of negativity vs. 16% for RNA) due to the lower analytical sensitivity compared to the real-time PCR for HCV-RNA [10, 11]. The antigen is cleared later, which possibly occurred because the circulating HCV core protein is available not only from virions but also from antigen-antibody complexes [8, 20] that have a longer half-life. When HCV-Ag has been related to treatment outcomes, its overall accuracy was the same as HCV-RNA.
Serological testing for HCV-Ag in patients treated for chronic HCV infection has already been described by several papers, either on patients treated with IFN-based regimens [11–13] or with DAAs [14, 15, 21]. The results of the latter treatments reported high consistency between HCV-RNA and HCV-Ag results both during treatment and at the end of the follow-up period. Our experience complements those studies with more details since we enrolled patients treated with different regimens and infected by different HCV genotypes, and the behavior of the two markers in SVR and in R was assessed separately.
Summarizing this evidence, HCV-RNA and HCV-Ag present similar kinetics in DAA treatment, either during treatment or during follow-up. As expected, HCV-Ag is less sensitive and is often negative in cases with very low levels of HCV-RNA. However, the current schedules do not include stopping rules because all patients are expected to complete the treatment course. Similarly, compared to the Peg-IFN-based treatment, a value for the baseline levels of HCV-RNA is no longer needed in order to tailor therapy, except in select cases [16], so the lower sensitivity of HCV-Ag does not seem to limit the performance of the treatment monitoring. Furthermore, low levels of HCV RNA during treatment or at the end of treatment are not indicative of non-adherence and do not predict a relapse [21, 22], and these are some of the reasons for moving towards a simplified monitoring strategy. Furthermore, the HCV-Ag assay has a very high specificity ranging from 99.8% in the original study [9] to 100% in subsequent observations [10, 19]. However, the potential advantages of using a serological test instead of a virological one is almost clear [9–12, 23]. Cresswell et al [23] demonstrated absolute clinical equivalence and substantial savings for utilizing HCV-Ag in place of HCV-RNA for the diagnosis of acute hepatitis C. Additionally, for treatment monitoring, HCV-Ag allows savings because it is less expensive than RNA [14, 23], does not need specialized technicians and, most of all, has a much faster turnaround time that allows a result to be available in 1 hour compared to up to 7 hours for HCV-RNA [12, 14]. Even though the economic savings may be small compared to the treatment cost, they may be help decrease the overall cost in economically developed countries and will definitely improve access to care for HCV worldwide with the aim of decreasing the prevalence and eventually the social and economic burden of the disease.
A possible limitation of our study is represented by the variety of DAA-based treatment regimens for our patients. Our choice was driven by the objective to report real-life experiences from a reference Hepatology Center, where patients are most frequently referred from other institutions and present with different clinical histories. The rate of virological failure that we observed depends on the heterogeneity of the study population (post-OLT, high percentage of advanced disease) and relies on the fact that a substantial number of patients were treated with a regimen that is no longer considered optimal according to current guidelines. This subset, albeit small, gave us the chance to observe perfect synchronism between viral and serological rebound, which confirms the results from previous studies [14, 21]. The barely significant difference in which there was an HCV-Ag decrease between SR and RR at W8 should not, in our opinion, lead clinicians to check HCV-Ag at this time point because this time point will not represent a stopping rule and will not lead to a change in treatment. However, it is suggested that RNA decay/clearance is linked to the halt in replicative activity due to DAAs action (pharmacological effect), whereas HCV-Ag clearance is linked to the elimination of infected cells that still contain virion components, so a negative HCV-Ag can reflect the complete clearance of infected cells.
Considering that viral relapse was diagnosed equally by HCV-RNA and by HCV-Ag, the latter may represent an alternative clinical value in settings where HCV-RNA is still the preferred or routine method for HCV monitoring.
In conclusion, our study provides further evidence of the clinical equivalency between HCV-RNA and HCV-Ag testing for assessing the response to DAA treatment for chronic HCV infection. A decision on what assay(s) to use in treatment monitoring will rely on the specific setting for the country/region where the therapy is dispensed, including reimbursement policies and continuous interaction and updates between the clinical and microbiology specialists of any given institution.
References
- 1. Kohli A, Shaffer A, Sherman A, Kottilil S. Treatment of hepatitis C: a systematic review. Jama. 2014;312(6):631–40. Epub 2014/08/15. pmid:25117132.
- 2. European Association for Study of L. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol. 2015;63(1):199–236. Epub 2015/04/26. pmid:25911336.
- 3. Chung RT, Gale M Jr., Polyak SJ, Lemon SM, Liang TJ, Hoofnagle JH. Mechanisms of action of interferon and ribavirin in chronic hepatitis C: Summary of a workshop. Hepatology. 2008;47(1):306–20. Epub 2007/12/29. pmid:18161743; PubMed Central PMCID: PMC2799164.
- 4. Lens S, Marino Z, Forns X. Efficacy of new direct acting antivirals in transplant recipients and patients with advanced disease. Digestive and liver disease: official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. 2014;46 Suppl 5:S197–205. Epub 2014/12/03. pmid:25458782.
- 5. Craxi A, Perno CF, Vigano M, Ceccherini-Silberstein F, Petta S, AdHoc Working P. From current status to optimization of HCV treatment: Recommendations from an expert panel. Digestive and liver disease: official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. 2016. Epub 2016/07/09. pmid:27388261.
- 6. Sarrazin C, Dierynck I, Cloherty G, Ghys A, Janssen K, Luo D, et al. An OPTIMIZE study retrospective analysis for management of telaprevir-treated hepatitis C virus (HCV)-infected patients by use of the Abbott RealTime HCV RNA assay. Journal of clinical microbiology. 2015;53(4):1264–9. Epub 2015/02/06. pmid:25653396; PubMed Central PMCID: PMC4365219.
- 7. Maasoumy B, Vermehren J, Welker MW, Bremer B, Perner D, Honer Zu Siederdissen C, et al. Clinical value of on-treatment HCV RNA levels during different sofosbuvir-based antiviral regimens. J Hepatol. 2016. Epub 2016/04/18. pmid:27085252.
- 8. Reed KE, Rice CM. Overview of hepatitis C virus genome structure, polyprotein processing, and protein properties. Current topics in microbiology and immunology. 2000;242:55–84. Epub 1999/12/11. pmid:10592656.
- 9. Bouvier-Alias M, Patel K, Dahari H, Beaucourt S, Larderie P, Blatt L, et al. Clinical utility of total HCV core antigen quantification: a new indirect marker of HCV replication. Hepatology. 2002;36(1):211–8. Epub 2002/06/27. pmid:12085367.
- 10. Medici MC, Furlini G, Rodella A, Fuertes A, Monachetti A, Calderaro A, et al. Hepatitis C virus core antigen: analytical performances, correlation with viremia and potential applications of a quantitative, automated immunoassay. Journal of clinical virology: the official publication of the Pan American Society for Clinical Virology. 2011;51(4):264–9. Epub 2011/05/31. pmid:21621454.
- 11. Chevaliez S, Soulier A, Poiteau L, Bouvier-Alias M, Pawlotsky JM. Clinical utility of hepatitis C virus core antigen quantification in patients with chronic hepatitis C. Journal of clinical virology: the official publication of the Pan American Society for Clinical Virology. 2014;61(1):145–8. Epub 2014/06/29. pmid:24973282.
- 12. Loggi E, Cursaro C, Scuteri A, Grandini E, Panno AM, Galli S, et al. Patterns of HCV-RNA and HCV core antigen in the early monitoring of standard treatment for chronic hepatitis C. Journal of clinical virology: the official publication of the Pan American Society for Clinical Virology. 2013;56(3):207–11. Epub 2012/12/19. pmid:23245628.
- 13. Kamal SM, Kassim S, El Gohary E, Fouad A, Nabegh L, Hafez T, et al. The accuracy and cost-effectiveness of hepatitis C core antigen assay in the monitoring of anti-viral therapy in patients with chronic hepatitis C genotype 4. Alimentary pharmacology & therapeutics. 2015;42(3):307–18. Epub 2015/05/29. pmid:26018116.
- 14. Aghemo A, Degasperi E, De Nicola S, Bono P, Orlandi A, D'Ambrosio R, et al. Quantification of Core Antigen Monitors Efficacy of Direct-acting Antiviral Agents in Patients With Chronic Hepatitis C Virus Infection. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association. 2016. Epub 2016/04/06. pmid:27046484.
- 15. Chevaliez S, Feld J, Cheng K, Wedemeyer H, Sarrazin C, Maasoumy B, et al. Clinical utility of HCV core antigen detection and quantification in the diagnosis and management of patients with chronic hepatitis C receiving an all-oral, interferon-free regimen. Antiviral therapy. 2016. Epub 2016/04/27. pmid:27115431.
- 16. European Association for the Study of the Liver. Electronic address eee. EASL Recommendations on Treatment of Hepatitis C 2016. J Hepatol. 2016. Epub 2016/09/27. pmid:27667367
- 17.
America TAAftSoLDatIDSo. Recommendations for Testing, Managing, and Treating Hepatitis C. Last Updated: April 12, 2017. www.hcvguidelinesorg. 2017.
- 18. Omata M, Kanda T, Wei L, Yu ML, Chuang WL, Ibrahim A, et al. APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing. Hepatology international. 2016;10(5):681–701. Epub 2016/05/28. pmid:27229718; PubMed Central PMCID: PMC5003900 the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Declaration of Helsinki 1975, as revised in 2008 (5). Informed consent was obtained from all patients included in the study. This article does not contain any studies with animal subjects. Conflict of interest Alaaeldin Ibrahim, Cosmas Rinaldi Adithya Lesmana, Mamun Al-Mahtab, George K. K. Lau, Barjesh C. Sharma, Jose Sollano, Manoj Kumar, Ankur Jindal, A. Kadir Dokmeci, Geofferey W. McCaughan, Darrell H. G. Crawford, Jafri Wasim, and Shiv Kumar Sarin declare that they have no conflict of interest. Masao Omata received fees for being a speaker, consultant, and advisory board member for Bayer Co., Boehringer Ingelheim, Bristol-Myers Squibb, Otsuka, Astellas, Gilead Sciences, Chugai, Mitsubishi Tanabe, Kyorin, Merck Sharp & Dohme, Dainippon Sumitomo, Vertex Pharmaceuticals, Takeda, and Zeria. Tatsuo Kanda received lecture fees from Chugai Pharmaceutical, MSD, Tanabe-Mitsubishi, Daiichi-Sankyo, Bristol-Myers Squibb, Gilead Sciences, and AbbVie and a research grant from Chugai and MSD. Lai Wei has research grants from BMS and Roche and received consulting fees from Abbott, AbbVie, BMS, Gilead, and Novartis. Ming-Lung Yu is a consultant and advisory board member and has grant support from AbbVie, BMS, Gilead, Roche, MSD, and Abbott. Wang-Long Chuang received speaker fees from Gilead, BMS, MSD, Roche, and Novartis and is a member of the following advisory boards: Gilead, AbbVie, and Roche. Saeed S. Hamid has conference travel support from Gilead. Jia-Horng Kao has served as a consultant for AbbVie, Bristol-Myers Squibb, Gilead Sciences, and Roche and has also served on speakers' bureaus for Roche, Bristol-Myers Squibb, Gilead Sciences, and Novartis. Osamu Yokosuka has research grants from Chugai Pharmaceutical, Bayer, MSD, Daiichi-Sankyo, Tanabe-Mitsubishi, and Bristol-Myers Squibb and received speaking fees from Merck Sharp and Dohme, Kowa Souku, Sysmex, Chugai Pharmaceutical Co., GlaxoSmithKline, Bristol-Myers Squibb, Ajinomoto-Seiyaku, Bayer, Abbott, Given Imaging, Mitsubishi Tanabe Pharm, Taiho Yakuhin, Dainippon Sumitomo Pharm, and Igaku-Seibutsugaku Institute.
- 19.
Organization WH. Guidelines on hepatitis B and C testing. Geneva: World Health Organization. 2017.
- 20. Morota K, Fujinami R, Kinukawa H, Machida T, Ohno K, Saegusa H, et al. A new sensitive and automated chemiluminescent microparticle immunoassay for quantitative determination of hepatitis C virus core antigen. Journal of virological methods. 2009;157(1):8–14. Epub 2009/01/13. pmid:19135481.
- 21. Rockstroh JK, Feld JJ, Chevaliez S, Cheng K, Wedemeyer H, Sarrazin C, et al. HCV core antigen as an alternate test to HCV RNA for assessment of virologic responses to all-oral, interferon-free treatment in HCV genotype 1 infected patients. Journal of virological methods. 2017;245:14–8. Epub 2017/04/01. pmid:28359920.
- 22. Sarrazin C, Wedemeyer H, Cloherty G, Cohen DE, Chevaliez S, Herman C, et al. Importance of very early HCV RNA kinetics for prediction of treatment outcome of highly effective all oral direct acting antiviral combination therapy. Journal of virological methods. 2015;214:29–32. Epub 2014/12/23. pmid:25528998.
- 23. Cresswell FV, Fisher M, Hughes DJ, Shaw SG, Homer G, Hassan-Ibrahim MO. Hepatitis C core antigen testing: a reliable, quick, and potentially cost-effective alternative to hepatitis C polymerase chain reaction in diagnosing acute hepatitis C virus infection. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2015;60(2):263–6. Epub 2014/10/11. pmid:25301216.